Although activation of EphA2 following ephrin-A1 ligand interaction blocks chemotactic migration of glioma and prostate cancer cells, EphA2 upregulation induces cell migration through a ligand-independent mechanism. Here, EPHA2 is linked to prostate carcinoma.